Spots Global Cancer Trial Database for metastatic renal cell carcinoma
Every month we try and update this database with for metastatic renal cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer | NCT00095108 | Melanoma Kidney Neoplasm... Metastases | Recombinant Hum... | 18 Years - | ZymoGenetics | |
| M8891 First in Human in Solid Tumors | NCT03138538 | Advanced Solid ... Metastatic Rena... | Part 1: M8891 | 18 Years - | EMD Serono | |
| Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. | NCT01339962 | Renal Cell Carc... | Non-interventio... | 18 Years - | Pfizer | |
| Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients | NCT02330783 | Metastatic Rena... | Bevacizumab Sorafenib | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | NCT03474497 | Non Small Cell ... Metastatic Mela... Metastatic Rena... Head and Neck S... | IL-2 Pembrolizumab Radiotherapy | 18 Years - | University of California, Davis | |
| Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma | NCT01491672 | Metastatic Rena... | RAD001 | 18 Years - | Novartis | |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | NCT05122546 | Advanced Clear ... Advanced Papill... Advanced Renal ... Advanced Sarcom... Metastatic Clea... Metastatic Papi... Metastatic Rena... Metastatic Sarc... Stage III Renal... Stage IV Renal ... Unresectable Cl... Unresectable Re... | Cabozantinib S-... Clostridium but... Nivolumab | 18 Years - | City of Hope Medical Center | |
| Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 | NCT03284385 | Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Stage III Renal... Stage IV Renal ... | Adavosertib | 18 Years - | National Cancer Institute (NCI) | |
| Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy | NCT03055013 | Metastatic Rena... Sarcomatoid Ren... Stage II Renal ... Stage III Renal... Unclassified Re... | Nephrectomy Nivolumab Patient Observa... | 18 Years - | National Cancer Institute (NCI) | |
| Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma | NCT01219751 | Metastatic Rena... | Sunitinib | 18 Years - | Asan Medical Center | |
| Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | NCT00100685 | Renal Cell Carc... Metastases | Volociximab (an... | 18 Years - | Abbott | |
| Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer | NCT06391099 | Clinical Stage ... Metastatic Cuta... Metastatic Rena... Stage IV Renal ... | Best Practice Biospecimen Col... Computed Tomogr... Dietary Interve... Educational Act... Glucose Measure... Ketone Measurem... Questionnaire A... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | NCT04140526 | Non Small Cell ... Advanced Solid ... Metastatic Mela... Metastatic Head... Metastatic Rena... Metastatic Colo... Sarcomas Metastatic Pros... Ovarian Cancer Small Cell Lung... Metastatic Brea... Pancreas Cancer Gastric Cancer Esophageal Canc... Gastroesophagea... Cervical Cancer Adenoid Cystic ... Salivary Gland ... Urothelial Carc... | ONC-392 Pembrolizumab Docetaxel | 18 Years - | OncoC4, Inc. | |
| Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | NCT00100685 | Renal Cell Carc... Metastases | Volociximab (an... | 18 Years - | Abbott | |
| Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer | NCT06391099 | Clinical Stage ... Metastatic Cuta... Metastatic Rena... Stage IV Renal ... | Best Practice Biospecimen Col... Computed Tomogr... Dietary Interve... Educational Act... Glucose Measure... Ketone Measurem... Questionnaire A... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy. | NCT03140176 | Metastatic Rena... | Sunitinib | 18 Years - | Pfizer | |
| Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma | NCT04974671 | Renal Cell Carc... Metastatic Rena... Oligoprogressiv... Progression | Stereotactic Bo... | 18 Years - | Yale University | |
| Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer | NCT01152801 | Metastatic Rena... | Everolimus (RAD... | 18 Years - | Novartis | |
| Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell Carcinoma | NCT04961320 | Metastatic Rena... Stage IV Renal ... | Occupational Th... Questionnaire A... | 18 Years - | City of Hope Medical Center | |
| Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer | NCT00923845 | Renal Cell Carc... Graft-Versus-Ho... Engraftment Syn... | Pentostatin Sirolimus Cyclophosphamid... Allogeneic Hema... Th2 rapa cells Donor Lymphocyt... Induction Thera... GVHD prophylaxi... Donor Hematopoi... | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases | NCT03967522 | Metastatic Rena... | Cabozantinib | 18 Years - | Centre Leon Berard | |
| Pazopanib in Second-line Therapy in Renal Cell Carcinoma | NCT01577784 | Metastatic Rena... | Pazopanib | 18 Years - | Associació per a la Recerca Oncologica, Spain | |
| IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma | NCT01265901 | Metastatic Rena... | Sunitinib GM-CSF Cyclophosphamid... IMA901 | 18 Years - | Immatics Biotechnologies GmbH | |
| Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma | NCT04049344 | Metastatic Rena... | Decitabine; Oxa... | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell Cancer | NCT04788095 | Metastatic Rena... Stage IV Renal ... | Behavioral Inte... Quality-of-Life... Questionnaire A... | 18 Years - | City of Hope Medical Center | |
| Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis | NCT00291369 | Metastatic Rena... | Interleukin-2 Interferon alfa medroxyprogeste... | 18 Years - | Centre Leon Berard | |
| Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma | NCT00203866 | Metastatic Rena... | G250 peptide IL-2 | 18 Years - | University of Chicago | |
| Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma | NCT01028638 | Metastatic Rena... | 89Zr-bevacizuma... | 18 Years - | University Medical Center Groningen | |
| A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | NCT06228326 | Lung Cancer, No... Lung Cancer Met... Solid Tumor, Ad... Advanced Cancer Lung Cancer, Sm... Metastatic Colo... Metastatic Rena... Metastatic Hepa... Metastatic Sarc... Metastatic Oste... | KB707 | 18 Years - | Krystal Biotech, Inc. | |
| Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases | NCT03967522 | Metastatic Rena... | Cabozantinib | 18 Years - | Centre Leon Berard | |
| PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy | NCT01415167 | Metastatic Rena... Metastatic Mela... | 18 Years - | Prometheus Laboratories | ||
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | NCT02419495 | Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re... | Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan | 18 Years - | M.D. Anderson Cancer Center | |
| Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing | NCT03109015 | Carcinoma, Rena... | Sunitinib Sunitinib | 18 Years - | Duke University | |
| Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. | NCT01339962 | Renal Cell Carc... | Non-interventio... | 18 Years - | Pfizer | |
| Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) | NCT02454478 | Carcinoma, Rena... | Lenvatinib Everolimus | 20 Years - | Eisai Inc. | |
| Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) | NCT01266837 | Metastatic Rena... Failure of Exac... | Everolimus | 18 Years - | iOMEDICO AG | |
| Urine Omics Predicting IO Therapy Responses in mRCC Patients | NCT04712305 | Metastatic Rena... | No intervention... | 20 Years - | National Taiwan University Hospital | |
| Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery | NCT04588246 | Anatomic Stage ... Metastatic Brea... Metastatic Dige... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Prognostic Stag... Recurrent Brain... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... | Memantine Quality-of-Life... Questionnaire A... Stereotactic Ra... Whole-Brain Rad... | 18 Years - | NRG Oncology | |
| Safety and Preliminary Efficacy of SBRT in Patients With Metastatic RCC Treated With Targeted or IO Therapy | NCT02864615 | Metastatic Rena... | SBRT | 18 Years - 75 Years | Kidney Cancer Research Bureau | |
| Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma | NCT00630409 | Metastatic Rena... | Gemcitabine Doxil | 18 Years - | University of Pittsburgh | |
| Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | NCT03149159 | Clear Cell Rena... Metastatic Rena... | Nivolumab Ipilimumab Steriotactic ra... | 18 Years - | Medical University of South Carolina | |
| Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | NCT00522249 | Carcinoma, Rena... | Pegylated Alfa ... sunitinib erlotinib | 18 Years - | The Methodist Hospital Research Institute | |
| Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | NCT03587662 | Metastatic Kidn... Metastatic Rena... SMARCB1 Negativ... Stage III Renal... Stage IV Renal ... | Doxorubicin Doxorubicin Hyd... Gemcitabine Gemcitabine Hyd... Ixazomib Ixazomib Citrat... | 12 Years - | M.D. Anderson Cancer Center | |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | NCT04514484 | Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi... | Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma | NCT01100242 | Metastatic Rena... | Velcade and Sor... | 18 Years - | New Mexico Cancer Care Alliance | |
| Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer | NCT01784978 | Metastatic Rena... | Sunitinib Everolimus | 18 Years - | Associació per a la Recerca Oncologica, Spain | |
| Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer | NCT00357760 | Metastatic Rena... | VEGF Trap | 18 Years - | National Cancer Institute (NCI) | |
| Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | NCT01223027 | Metastatic Rena... | Dovitinib Sorafenib | 18 Years - | Novartis | |
| Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations | NCT03786796 | Renal Cell Carc... Metastatic Rena... Kidney Cancer Renal Carcinoma Kidney Cancer M... | Olaparib | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery | NCT04588246 | Anatomic Stage ... Metastatic Brea... Metastatic Dige... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Prognostic Stag... Recurrent Brain... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... | Memantine Quality-of-Life... Questionnaire A... Stereotactic Ra... Whole-Brain Rad... | 18 Years - | NRG Oncology | |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | NCT05092373 | Advanced Breast... Advanced Endome... Advanced Fallop... Advanced Hepato... Advanced Malign... Advanced Malign... Advanced Malign... Advanced Ovaria... Advanced Primar... Advanced Renal ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Malignant Abdom... Malignant Solid... Metastatic Brea... Metastatic Endo... Metastatic Fall... Metastatic Hepa... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Metastatic Rena... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Fallo... Stage III Hepat... Stage III Ovari... Stage III Prima... Stage III Renal... Stage III Uteri... Stage IIIA Fall... Stage IIIA Hepa... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Hepa... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Fallop... Stage IV Hepato... Stage IV Ovaria... Stage IV Primar... Stage IV Renal ... Stage IV Uterin... Stage IVA Fallo... Stage IVA Hepat... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVB Fallo... Stage IVB Hepat... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri... | Atezolizumab Cabozantinib S-... Nab-paclitaxel Tumor Treating ... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma | NCT00848640 | Metastatic Rena... | Sorafenib | 18 Years - 60 Years | Egyptian Foundation For Cancer Research | |
| Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma | NCT05263050 | Metastatic Rena... Clear-cell Meta... | Cabozantinib Nivolumab | 18 Years - | Fox Chase Cancer Center | |
| A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | NCT03115801 | Metastatic Rena... Metastatic Urot... | Nivolumab Atezolizumab Radiation & imm... Pembrolizumab | 19 Years - 90 Years | Weill Medical College of Cornell University | |
| Efficacy of Activated Lymphocytes in Renal Cell Carcinoma. | NCT00151645 | Metastatic Rena... | activated lymph... | 18 Years - 70 Years | Rennes University Hospital | |
| Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma | NCT04919122 | Metastatic Rena... | 19 Years - | Duke University | ||
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | NCT03682289 | Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Metastatic Urot... Metastatic Panc... Stage III Pancr... Stage III Renal... Stage IV Pancre... Stage IV Renal ... Endometrial Can... Metastatic Cast... | Ceralasertib Olaparib Durvalumab | 18 Years - | University of California, San Francisco | |
| Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma | NCT01481870 | Metastatic Rena... | Sorafenib-sunit... Sunitinib-soraf... | 20 Years - 80 Years | Yamagata University | |
| Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer | NCT04337970 | Kidney Cancer Renal Cell Carc... Unresectable Re... Metastatic Rena... | Talazoparib Axitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer | NCT01152801 | Metastatic Rena... | Everolimus (RAD... | 18 Years - | Novartis | |
| Bevacizumab in Metastatic Renal Cancer | NCT02627144 | Renal Cell Canc... | Bevacizumab Interferon alph... | 18 Years - | Hoffmann-La Roche | |
| TIL Therapy for Metastatic Renal Cell Carcinoma | NCT02926053 | Metastatic Rena... | Surgical remova... Cyclophosphamid... Fludarabine TIL infusion Interleukin-2 | 18 Years - 70 Years | Herlev Hospital | |
| Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma | NCT03519542 | Metastatic Rena... | Sunitinib | 18 Years - | Spanish Oncology Genito-Urinary Group | |
| A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) | NCT06284564 | Metastatic Rena... | Evolocumab Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma | NCT00606866 | Metastatic Rena... | placebo Sorafenib Sorafenib | 18 Years - | University of Chicago | |
| Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy | NCT03891485 | RCC Metastatic Rena... | Immunological a... | - | National Cancer Institute, Naples | |
| Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib | NCT02019576 | Clear Cell Meta... | Stereotactic ra... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma | NCT00056173 | Carcinoma, Rena... Metastases, Neo... | GTI-2040 | 18 Years - | Aptose Biosciences Inc. | |
| A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma | NCT00515697 | Metastatic Rena... | Ramucirumab | 18 Years - | Eli Lilly and Company | |
| Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) | NCT02060370 | Genitourinary C... Kidney Cancer | Sunitinib Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248 | NCT00531544 | Metastatic Rena... | SU011248 | 18 Years - 85 Years | King Faisal Specialist Hospital & Research Center | |
| Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma | NCT00318110 | Metastatic Rena... | NST using MUD f... | 18 Years - 65 Years | Center for International Blood and Marrow Transplant Research | |
| Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy | NCT03055013 | Metastatic Rena... Sarcomatoid Ren... Stage II Renal ... Stage III Renal... Unclassified Re... | Nephrectomy Nivolumab Patient Observa... | 18 Years - | National Cancer Institute (NCI) | |
| Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy | NCT05112627 | Metastatic Rena... Stage IV Renal ... | Biospecimen Col... | 18 Years - | Mayo Clinic | |
| A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | NCT03115801 | Metastatic Rena... Metastatic Urot... | Nivolumab Atezolizumab Radiation & imm... Pembrolizumab | 19 Years - 90 Years | Weill Medical College of Cornell University | |
| A Research Study for Patients With Metastatic Renal Cell Carcinoma | NCT00106613 | Carcinoma, Rena... Neoplasm Metast... | FK228 (romideps... | 18 Years - | Celgene | |
| Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma | NCT05816642 | Metastatic Rena... | sunitinib or pa... PD-1 inhibitor ... | - | RenJi Hospital | |
| A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy | NCT01693822 | Clear-cell Meta... | Axitinib | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery | NCT02595918 | Clear Cell Rena... Metastatic Rena... Stage I Renal C... Stage II Renal ... Stage III Renal... Stage IV Renal ... | Metastasectomy Nephrectomy Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma | NCT03149822 | Metastatic Rena... | Cabozantinib Pembrolizumab | 18 Years - 100 Years | University of Colorado, Denver |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
